Investigating a new treatment approach for advanced prostate cancer
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
['FUNDING_R01'] · CEDARS-SINAI MEDICAL CENTER · NIH-10943867
This study is looking at a new way to help men with castration-resistant prostate cancer by using a combination of two treatments to see if they can work better together and improve how well the cancer responds to therapy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CEDARS-SINAI MEDICAL CENTER (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-10943867 on ClinicalTrials.gov |
What this research studies
This research aims to explore a novel treatment strategy for patients with castration-resistant prostate cancer by combining androgen receptor signaling inhibitors with a CD105 antagonist called carotuximab. The study focuses on understanding how this combination can overcome resistance to standard therapies, which often fail over time. By examining the interactions between these treatments and the tumor environment, researchers hope to identify effective ways to enhance treatment responses in patients. The approach involves both laboratory studies and clinical trials to assess safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded to standard androgen receptor signaling inhibitors.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer who have become resistant to current therapies.
How similar studies have performed: Previous studies have shown promise in combining targeted therapies for prostate cancer, suggesting that this approach may yield beneficial results.
Where this research is happening
LOS ANGELES, UNITED STATES
- CEDARS-SINAI MEDICAL CENTER — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BHOWMICK, NEIL A. — CEDARS-SINAI MEDICAL CENTER
- Study coordinator: BHOWMICK, NEIL A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.